#cefepime

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cefepime Market Size, Share & Trends Analysis Report By Type (Oral Formulations, Injectable, and Combination Therapies), Application (Pneumonia, Meningitis, Urinary Tract Infections, Bloodstream Infections, Skin and Soft Tissue Infections, and Intra-abdominal Infections), Distribution Channel (Hospital Pharmacies and Retail Pharmacies),-Market Outlook And Industry Analysis 2034"

Global Cefepime Market is valued at US$ 2.0 Bn in 2024 and it is expected to reach US$ 3.86 Bn by 2034, with a CAGR of 7.0% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3274

Cefepime, a fourth-generation cephalosporin antibiotic, is indicated for the management of a wide spectrum of serious bacterial infections. Its mechanism of action involves the inhibition of bacterial cell wall synthesis, resulting in the eradication of susceptible pathogens. Cefepime exhibits activity against both Gram-positive and Gram-negative bacteria, including strains resistant to earlier-generation cephalosporins. It is commonly utilized in the treatment of severe infections such as pneumonia, intra-abdominal infections, skin and soft tissue infections, urinary tract infections, and febrile neutropenia.

The global cefepime market is mature and largely consolidated, with generic manufacturers dominating due to the drug’s established presence in hospital formularies. The market is characterized by high-volume, price-sensitive competition among multiple players. Sustained demand is underpinned by cefepime’s continued inclusion in clinical treatment guidelines for critical bacterial infections and its strategic application within antimicrobial stewardship programs as a targeted therapeutic agent. The market is further defined by the predominance of injectable formulations, reflecting its critical role in hospital-based care for severe infections.

List of Prominent Players in the Cefepime Market:

Hetero Labs Limited

Dr. Reddy's Laboratories

Mylan Pharmaceuticals

Cipla Limited

Lupin Pharmaceuticals

Sandoz

Aurobindo Pharma

Teva Pharmaceuticals

Zydus Cadila

Sun Pharmaceutical Industries Ltd.

AbbVie Inc.

Novartis AG

Fresenius Kabi

Bayer AG

Eli Lilly and Company

Shanghai United Cell Biotechnology Co., Ltd.

WuXi AppTec

BioRidge Pharma

Hikma Pharmaceuticals PLC

Alkem Laboratories Ltd.

Read Overview Report- https://www.insightaceanalytic.com/report/cefepime-market/3274

Market Dynamics

Drivers:

The global cefepime market is primarily driven by the increasing prevalence of bacterial infections, particularly those caused by antibiotic-resistant strains. The rising incidence of hospital-acquired infections, especially among immunocompromised patients, further supports market growth. Expanding utilization of cefepime in emerging markets, alongside ongoing enhancements in healthcare infrastructure, is contributing to market development. Heightened awareness of antibiotic resistance risks has amplified demand for effective therapeutic options such as cefepime. Additionally, the aging global population, which is more vulnerable to infectious diseases, provides sustained growth opportunities for the market.

Challenges:

The cefepime market faces several constraints that may impede expansion. Strict regulatory requirements for drug approval can delay the introduction of new formulations. The emergence and proliferation of antibiotic-resistant bacteria threaten the drug’s clinical effectiveness, potentially limiting its usage. Furthermore, the high costs associated with antibiotic development and production restrict accessibility in low-income regions, which may constrain broader market growth.

Regional Trends:

In 2024, North America retained its leadership position in the cefepime market, supported by an advanced healthcare infrastructure, high incidence of bacterial infections, and a strong presence of pharmaceutical manufacturers. The region’s focus on infection control, healthcare innovation, and substantial investment in medical research and development underpins continued demand for cefepime and reinforces North America’s dominant market position.

The Asia-Pacific region is anticipated to register the highest growth rate over the forecast period. Factors such as rising population, increasing healthcare awareness, and improved access to medical services are driving strong demand for effective antibiotic therapies, positioning the region as a key growth market for cefepime globally.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3274

Recent Developments:

In January 2025, the global healthcare company Fresenius Kabi announced the launch of a new injectable formulation of cefepime, a critical broad-spectrum antibiotic. This launch was a strategic initiative to broaden the company's existing portfolio of ready-to-sterilize antibiotics, which are essential for hospital and clinical use.

Segmentation of Cefepime Market-

By Type-

Oral Formulations

Injectable

Combination Therapies

By Application -

Pneumonia

Meningitis

Urinary Tract Infections

Bloodstream Infections

Skin and Soft Tissue Infections

Intra-abdominal Infections

By Distribution Channel-

Hospital Pharmacies

Retail Pharmacies

By Region-

North America-

The US

Canada

Europe-

Germany

The UK

France

Italy

Spain

Rest of Europe

Asia-Pacific-

China

Japan

India

South Korea

South East Asia

Rest of Asia Pacific

Latin America-

Brazil

Argentina

Mexico

Rest of Latin America

 Middle East & Africa-

GCC Countries

South Africa

Rest of Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:

InsightAce Analytic Pvt. Ltd.

Visit: https://www.insightaceanalytic.com/

Tel : +1 607 400-7072

Asia: +91 79 72967118

Cefepime 88040-23-7 INGREDIENTUNIICASINCHI KEYCefepime hydrochlorideI8X1O0607P123171-59-5LRAJHPGSGBRUJN-OMIVUECESA-N Cefepime CAS Registry Number: 88040-23-7 CAS Name: 1-[[(6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium inner salt Additional…

Common Brand Names: Maxipime

Therapeutic Class: A cephalosporin antibiotic

Common Injectable Dosage Forms:

Powder for Injection: 500 mg in 15 mL vials, 1 g in 15 mL vials, ADD-vantage vials, and 100 mL piggyback bottles, and 2 g in 20 mL vials, ADD-vantage vials, and 100 mL piggyback bottles. *ADD-vantage is a trademark of Abbott Labs.

Dosage Ranges:

Moderate to severe pneumonia due to S. pneumoniae, P. aeruginosa, K. pneumoniae, or Enterobacter species: 1-2 g IV every 12 hours for 10 days.

Empiric therapy for febrile neutropenic patients: 2 g IV every 8 hours for at least 7 days.

Mild to moderate uncomplicated urinary tract infections, including pyelonephritis, due to E. coli, K. pneumoniae, or P. mirabilis: 0.5-1 g IV or IM (E. Coli only) every 12 hours for 7-10 days.

Severe uncomplicated or complicated urinary tract infections, including pyelonephritis, due to E. coli or K. pneumoniae: 2 g every 12 hours for 10 days.

Moderate to severe uncomplicated skin and skin structure infections due to S. aureus or S. pyogenes: 2 g IV every 12 hours for 10 days.

Complicated intra-abdominal infections (use with metronidazole) caused by E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, or B. fragilis: 2 g IV every 12 hours for 7-10 days.

Dosing schedule for patients with impaired renal function:

Normal dose (CrC >60 mL/min): 500 mg every 12 hours, 1 g every 12 hours, 2 g every 12 hours, or 2 g every 8 hours.

CrC 30-60 mL/min: 500 mg every 24 hours, 1 g every 24 hours, 2 g every 24 hours, or 2 g every 12 hours.

CrC 11-29 mL/min: 500 mg every 24 hours, 500 mg every 24 hours, 1 g every 24 hours, or 2 g every 24 hours.

CrC <11 mL/min: 250 mg every 24 hours, 250 mg every 24 hours, 500 mg every 24 hours, or 1 g every 24 hours.

CAPD: 500 mg every 48 hours, 1 g every 48 hours, 2 g every 48 hours, 2 g every 48 hours.

Hemodialysis: 1 g on day one, then 500 mg every 24 hours thereafter.

Administration and Stability: Maxipime in the dry state should be stored between 2°-25°C (36°-77°F) and protected from light. Maxipime is compatible at concentrations between 1-40 mg/mL with the following IV infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringer's and 5% Dextrose Injection, Normosol-R, and Normosol-M in 5% Dextrose Injection. Maxipime in ADD-vantage vials are compatible in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. These solutions may be stored up to 24 hours at 20°-25°C (68°-77°F) for 7 days at 2°-8°C (36°-46°F). IV solutions should be administered over 30 minutes. PH 4-6

Pharmacology/Pharmacokinetics: Cefepime exerts its bactericidal activity by inhibition on mucopeptide synthesis in the bacterial cell wall. It is widely bioavailable following IM or IV injection, with peak levels occurring in 1-2 hours after IM dosage. The drug is eliminated by renal tubular secretion. Spectrum of activity includes many gram-positive aerobic bacteria (S. aureus, S. pneumoniae, S. pyogenes, and viridans-group streptococci) and gram-negative aerobic bacteria (Enterobacter species, E. coli, K. pneumoniae, P. mirabilis, P. aeruginosa).

Drug and Lab Interactions: May give false-positive Coombs’ test. May give a false-positive reaction for glucose in the urine when using Clinitest tablets. Increases potential of nephrotoxicity and ototoxicity when used with aminoglycosides. Nephrotoxicity risk increases when used with strong diuretics such as furosemide.

Contraindications/Precautions: Contraindicated in patients hypersensitive to cephalosporins, penicillins, or other beta-lactam antibiotics. Use with caution and with dosage adjustments in patients with impaired renal function. As with nearly all antibacterial agents, pseudomembranous colitis can occur with use. This diagnosis should be considered in patients reporting severe or persistent diarrhea. Use with caution in patients with a history of GI disease, especially colitis. Pregnancy Category B.

Monitoring Parameters: Watch for signs of anaphylaxis, culture and sensitivity of specimen.

Adverse Effects: The most common adverse effects are local reactions including phlebitis, pain and/or inflammation. May also cause rash.

Our teenalabs are the fast developing sterile bulk drug manufacturers and formulations in India. Cefepime HCL sterile is used to treat infections .The Company has a grounded customer base in India just as everywhere on the globe. We offer both innovative work to meet the APIs prerequisites of drug and mass medication.

                                            This medication has a place with a gathering of medications known as cephalosporin anti-infection agents. Cefepime infusion is utilized to treat certain diseases brought about by microbes including pneumonia, and skin, urinary plot, and kidney contaminations. It is utilized in mix with metronidazole to treat diseases. This is additionally used to treat patients who have fever and are at high danger for contamination since they have a low number of white platelets. It is in a class of drugs called cephalosporin anti-toxins. It works by eliminating microorganisms.